Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Analysts

Shares of Annexon, Inc. (NASDAQ:ANNX) have received a consensus recommendation of “Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $15.80.

ANNX has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Trading Down 0.4 %

ANNX opened at $2.66 on Thursday. The stock has a market cap of $291.83 million, a PE ratio of -2.53 and a beta of 1.14. Annexon has a 1 year low of $2.30 and a 1 year high of $8.40. The stock’s 50 day simple moving average is $3.60 and its 200-day simple moving average is $5.26.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Equities analysts forecast that Annexon will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Annexon

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Annexon in the fourth quarter worth $59,000. CANADA LIFE ASSURANCE Co acquired a new position in Annexon in the fourth quarter worth $77,000. E Fund Management Co. Ltd. boosted its stake in Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after purchasing an additional 4,086 shares in the last quarter. Forefront Analytics LLC boosted its stake in Annexon by 56.8% in the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after purchasing an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Annexon in the fourth quarter worth $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.